Fedratinib

A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
25 patients (estimated)
Sponsors
Moffitt Cancer Center
Collaborators
Bristol Myers Squibb
Tags
JAK2 Inhibitor, Kinase Inhibitor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1880
NCT Identifier
NCT05177211

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.